Mouabbi, Jason A. http://orcid.org/0000-0001-8689-6845
Raghavendra, Akshara Singareeka http://orcid.org/0000-0002-6425-4400
Bassett, Roland L. Jr http://orcid.org/0000-0002-4534-2042
Hassan, Amy
Tripathy, Debu http://orcid.org/0000-0002-5711-2404
Layman, Rachel M.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA016672)
Article History
Received: 4 September 2022
Accepted: 2 December 2022
First Online: 20 December 2022
Competing interests
: The authors declare the following disclosures: J.A.M.: consulting fees from GE Healthcare, Genentech and Cardinal Health. A.H.: consulting fees for AIM Specialty Health, Oncology Pathways Program. D.T.: Research support from Novartis and Pfizer; consulting fees from Novartis, Pfizer, Exact Sciences, GlaxoSmithKline and AstraZeneca. R.M.L.: research support from Pfizer, Eli Lilly, Novartis, GlaxoSmithKline, Puma, Zentalis, and Celcuity; consulting fees from Pfizer, Eli Lilly, Novartis, and Celcuity. The remaining authors declare no competing interests.